Curocell
Curocell Inc., a cell gene therapy development company, engages in the development and manufacturing of pharmaceuticals. It provides research and development services; and OVercome Immune Suppression (OVIS), a proprietary platform technology designed to get away from exhaustion induced by immune checkpoint receptors. The company is also involved in the development of CD19 CAR-T treatment, blood c… Read more
Curocell (372320) - Net Assets
Latest net assets as of September 2025: ₩19.88 Billion KRW
Based on the latest financial reports, Curocell (372320) has net assets worth ₩19.88 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩113.05 Billion) and total liabilities (₩93.17 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩19.88 Billion |
| % of Total Assets | 17.59% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Curocell - Net Assets Trend (2021–2024)
This chart illustrates how Curocell's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Curocell (2021–2024)
The table below shows the annual net assets of Curocell from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩29.45 Billion | -50.16% |
| 2023-12-31 | ₩59.10 Billion | +224.16% |
| 2022-12-31 | ₩-47.60 Billion | -289.01% |
| 2021-12-31 | ₩-12.24 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Curocell's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10697620352000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩7.10 Billion | 24.10% |
| Other Components | ₩221.45 Billion | 751.84% |
| Total Equity | ₩29.45 Billion | 100.00% |
Curocell Competitors by Market Cap
The table below lists competitors of Curocell ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Microvast Holdings Inc
NASDAQ:MVST
|
$303.33 Million |
|
AUBAY TECHNOL. INH.EO 05
F:BAQ
|
$303.38 Million |
|
Sysgration Ltd
TWO:5309
|
$303.56 Million |
|
ERMENEGILDO ZEG.DL -0001
F:JN0
|
$303.56 Million |
|
Amarin Corporation PLC
NASDAQ:AMRN
|
$303.32 Million |
|
Shenzhen Longood Intelligent Electric Co Ltd Class A
SHE:300543
|
$303.32 Million |
|
Canandaigua National Corporation
PINK:CNND
|
$303.32 Million |
|
China Catalyst Holding Co. Ltd. A
SHG:688267
|
$303.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Curocell's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 59,099,540,500 to 29,454,229,700, a change of -29,645,310,800 (-50.2%).
- Net loss of 38,239,224,340 reduced equity.
- Share repurchases of 1,555,925,280 reduced equity.
- New share issuances of 1,555,925,280 increased equity.
- Other factors increased equity by 8,593,913,540.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-38.24 Billion | -129.83% |
| Share Repurchases | ₩1.56 Billion | -5.28% |
| Share Issuances | ₩1.56 Billion | +5.28% |
| Other Changes | ₩8.59 Billion | +29.18% |
| Total Change | ₩- | -50.16% |
Book Value vs Market Value Analysis
This analysis compares Curocell's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 22.49x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | ₩-898.85 | ₩46650.00 | x |
| 2022-12-31 | ₩-3496.57 | ₩46650.00 | x |
| 2023-12-31 | ₩4341.49 | ₩46650.00 | x |
| 2024-12-31 | ₩2074.35 | ₩46650.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Curocell utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -129.83%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.45x
- Recent ROE (-129.83%) is below the historical average (-44.97%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | ₩-52.35 Billion |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | ₩-34.13 Billion |
| 2023 | -50.04% | 0.00% | 0.00x | 1.78x | ₩-35.48 Billion |
| 2024 | -129.83% | 0.00% | 0.00x | 2.45x | ₩-41.18 Billion |
Industry Comparison
This section compares Curocell's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Curocell (372320) | ₩19.88 Billion | 0.00% | 4.69x | $303.33 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |